Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial

Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arisi...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Lancet. Haematology Ročník 4; číslo 6; s. e258
Hlavní autori:	Innerhofer, Petra, Fries, Dietmar, Mittermayr, Markus, Innerhofer, Nicole, von Langen, Daniel, Hell, Tobias, Gruber, Gottfried, Schmid, Stefan, Friesenecker, Barbara, Lorenz, Ingo H, Ströhle, Mathias, Rastner, Verena, Trübsbach, Susanne, Raab, Helmut, Treml, Benedikt, Wally, Dieter, Treichl, Benjamin, Mayr, Agnes, Kranewitter, Christof, Oswald, Elgar
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.06.2017
Predmet:	Adolescent Adult Aged Aged, 80 and over Blood Coagulation Factors - therapeutic use Female Hemorrhage - drug therapy Hemorrhage - etiology Humans Male Middle Aged Plasma Treatment Outcome Wounds and Injuries - complications Young Adult
ISSN:	2352-3026, 2352-3026
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure. This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria). Patients with trauma aged 18-80 years, with an Injury Severity Score (ISS) greater than 15, bleeding signs, and plasmatic coagulopathy identified by abnormal fibrin polymerisation or prolonged coagulation time using rotational thromboelastometry (ROTEM) were eligible. Patients with injuries that were judged incompatible with survival, cardiopulmonary resuscitation on the scene, isolated brain injury, burn injury, avalanche injury, or prehospital coagulation therapy other than tranexamic acid were excluded. We used a computer-generated randomisation list, stratification for brain injury and ISS, and closed opaque envelopes to randomly allocate patients to treatment with FFP (15 mL/kg of bodyweight) or CFC (primarily fibrinogen concentrate [50 mg/kg of bodyweight]). Bleeding management began immediately after randomisation and continued until 24 h after admission to the intensive care unit. The primary clinical endpoint was multiple organ failure in the modified intention-to-treat population (excluding patients who discontinued treatment). Reversal of coagulopathy and need for massive transfusions were important secondary efficacy endpoints that were the reason for deciding the continuation or termination of the trial. This trial is registered with ClinicalTrials.gov, number NCT01545635. Between March 3, 2012, and Feb 20, 2016, 100 out of 292 screened patients were included and randomly allocated to FFP (n=48) and CFC (n=52). Six patients (four in the FFP group and two in the CFC group) discontinued treatment because of overlooked exclusion criteria or a major protocol deviation with loss of follow-up. 44 patients in the FFP group and 50 patients in the CFC group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients in the FFP group who required rescue therapy compared with those in the CFC group (23 [52%] in the FFP group vs two [4%] in the CFC group; odds ratio [OR] 25·34 [95% CI 5·47-240·03], p<0·0001) and increased needed for massive transfusion (13 [30%] in the FFP group vs six [12%] in the CFC group; OR 3·04 [0·95-10·87], p=0·042) in the FFP group. Multiple organ failure occurred in 29 (66%) patients in the FFP group and in 25 (50%) patients in the CFC group (OR 1·92 [95% CI 0·78-4·86], p=0·15). Our results underline the importance of early and effective fibrinogen supplementation for severe clotting failure in multiple trauma. The available sample size in our study appears sufficient to make some conclusions that first-line CFC is superior to FFP. None.
AbstractList	Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure.BACKGROUNDEffective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure.This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria). Patients with trauma aged 18-80 years, with an Injury Severity Score (ISS) greater than 15, bleeding signs, and plasmatic coagulopathy identified by abnormal fibrin polymerisation or prolonged coagulation time using rotational thromboelastometry (ROTEM) were eligible. Patients with injuries that were judged incompatible with survival, cardiopulmonary resuscitation on the scene, isolated brain injury, burn injury, avalanche injury, or prehospital coagulation therapy other than tranexamic acid were excluded. We used a computer-generated randomisation list, stratification for brain injury and ISS, and closed opaque envelopes to randomly allocate patients to treatment with FFP (15 mL/kg of bodyweight) or CFC (primarily fibrinogen concentrate [50 mg/kg of bodyweight]). Bleeding management began immediately after randomisation and continued until 24 h after admission to the intensive care unit. The primary clinical endpoint was multiple organ failure in the modified intention-to-treat population (excluding patients who discontinued treatment). Reversal of coagulopathy and need for massive transfusions were important secondary efficacy endpoints that were the reason for deciding the continuation or termination of the trial. This trial is registered with ClinicalTrials.gov, number NCT01545635.METHODSThis single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria). Patients with trauma aged 18-80 years, with an Injury Severity Score (ISS) greater than 15, bleeding signs, and plasmatic coagulopathy identified by abnormal fibrin polymerisation or prolonged coagulation time using rotational thromboelastometry (ROTEM) were eligible. Patients with injuries that were judged incompatible with survival, cardiopulmonary resuscitation on the scene, isolated brain injury, burn injury, avalanche injury, or prehospital coagulation therapy other than tranexamic acid were excluded. We used a computer-generated randomisation list, stratification for brain injury and ISS, and closed opaque envelopes to randomly allocate patients to treatment with FFP (15 mL/kg of bodyweight) or CFC (primarily fibrinogen concentrate [50 mg/kg of bodyweight]). Bleeding management began immediately after randomisation and continued until 24 h after admission to the intensive care unit. The primary clinical endpoint was multiple organ failure in the modified intention-to-treat population (excluding patients who discontinued treatment). Reversal of coagulopathy and need for massive transfusions were important secondary efficacy endpoints that were the reason for deciding the continuation or termination of the trial. This trial is registered with ClinicalTrials.gov, number NCT01545635.Between March 3, 2012, and Feb 20, 2016, 100 out of 292 screened patients were included and randomly allocated to FFP (n=48) and CFC (n=52). Six patients (four in the FFP group and two in the CFC group) discontinued treatment because of overlooked exclusion criteria or a major protocol deviation with loss of follow-up. 44 patients in the FFP group and 50 patients in the CFC group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients in the FFP group who required rescue therapy compared with those in the CFC group (23 [52%] in the FFP group vs two [4%] in the CFC group; odds ratio [OR] 25·34 [95% CI 5·47-240·03], p<0·0001) and increased needed for massive transfusion (13 [30%] in the FFP group vs six [12%] in the CFC group; OR 3·04 [0·95-10·87], p=0·042) in the FFP group. Multiple organ failure occurred in 29 (66%) patients in the FFP group and in 25 (50%) patients in the CFC group (OR 1·92 [95% CI 0·78-4·86], p=0·15).FINDINGSBetween March 3, 2012, and Feb 20, 2016, 100 out of 292 screened patients were included and randomly allocated to FFP (n=48) and CFC (n=52). Six patients (four in the FFP group and two in the CFC group) discontinued treatment because of overlooked exclusion criteria or a major protocol deviation with loss of follow-up. 44 patients in the FFP group and 50 patients in the CFC group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients in the FFP group who required rescue therapy compared with those in the CFC group (23 [52%] in the FFP group vs two [4%] in the CFC group; odds ratio [OR] 25·34 [95% CI 5·47-240·03], p<0·0001) and increased needed for massive transfusion (13 [30%] in the FFP group vs six [12%] in the CFC group; OR 3·04 [0·95-10·87], p=0·042) in the FFP group. Multiple organ failure occurred in 29 (66%) patients in the FFP group and in 25 (50%) patients in the CFC group (OR 1·92 [95% CI 0·78-4·86], p=0·15).Our results underline the importance of early and effective fibrinogen supplementation for severe clotting failure in multiple trauma. The available sample size in our study appears sufficient to make some conclusions that first-line CFC is superior to FFP.INTERPRETATIONOur results underline the importance of early and effective fibrinogen supplementation for severe clotting failure in multiple trauma. The available sample size in our study appears sufficient to make some conclusions that first-line CFC is superior to FFP.None.FUNDINGNone. Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure. This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria). Patients with trauma aged 18-80 years, with an Injury Severity Score (ISS) greater than 15, bleeding signs, and plasmatic coagulopathy identified by abnormal fibrin polymerisation or prolonged coagulation time using rotational thromboelastometry (ROTEM) were eligible. Patients with injuries that were judged incompatible with survival, cardiopulmonary resuscitation on the scene, isolated brain injury, burn injury, avalanche injury, or prehospital coagulation therapy other than tranexamic acid were excluded. We used a computer-generated randomisation list, stratification for brain injury and ISS, and closed opaque envelopes to randomly allocate patients to treatment with FFP (15 mL/kg of bodyweight) or CFC (primarily fibrinogen concentrate [50 mg/kg of bodyweight]). Bleeding management began immediately after randomisation and continued until 24 h after admission to the intensive care unit. The primary clinical endpoint was multiple organ failure in the modified intention-to-treat population (excluding patients who discontinued treatment). Reversal of coagulopathy and need for massive transfusions were important secondary efficacy endpoints that were the reason for deciding the continuation or termination of the trial. This trial is registered with ClinicalTrials.gov, number NCT01545635. Between March 3, 2012, and Feb 20, 2016, 100 out of 292 screened patients were included and randomly allocated to FFP (n=48) and CFC (n=52). Six patients (four in the FFP group and two in the CFC group) discontinued treatment because of overlooked exclusion criteria or a major protocol deviation with loss of follow-up. 44 patients in the FFP group and 50 patients in the CFC group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients in the FFP group who required rescue therapy compared with those in the CFC group (23 [52%] in the FFP group vs two [4%] in the CFC group; odds ratio [OR] 25·34 [95% CI 5·47-240·03], p<0·0001) and increased needed for massive transfusion (13 [30%] in the FFP group vs six [12%] in the CFC group; OR 3·04 [0·95-10·87], p=0·042) in the FFP group. Multiple organ failure occurred in 29 (66%) patients in the FFP group and in 25 (50%) patients in the CFC group (OR 1·92 [95% CI 0·78-4·86], p=0·15). Our results underline the importance of early and effective fibrinogen supplementation for severe clotting failure in multiple trauma. The available sample size in our study appears sufficient to make some conclusions that first-line CFC is superior to FFP. None.
Author	Innerhofer, Petra Gruber, Gottfried Ströhle, Mathias Wally, Dieter Mittermayr, Markus Oswald, Elgar Hell, Tobias Raab, Helmut Rastner, Verena von Langen, Daniel Treml, Benedikt Friesenecker, Barbara Mayr, Agnes Schmid, Stefan Treichl, Benjamin Fries, Dietmar Innerhofer, Nicole Trübsbach, Susanne Lorenz, Ingo H Kranewitter, Christof
Author_xml	– sequence: 1 givenname: Petra surname: Innerhofer fullname: Innerhofer, Petra email: Petra.Innerhofer@tirol-kliniken.at organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: Petra.Innerhofer@tirol-kliniken.at – sequence: 2 givenname: Dietmar surname: Fries fullname: Fries, Dietmar organization: Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 3 givenname: Markus surname: Mittermayr fullname: Mittermayr, Markus organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 4 givenname: Nicole surname: Innerhofer fullname: Innerhofer, Nicole organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 5 givenname: Daniel surname: von Langen fullname: von Langen, Daniel organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 6 givenname: Tobias surname: Hell fullname: Hell, Tobias organization: Department of Mathematics, Faculty of Mathematics, Computer Science and Physics, University of Innsbruck, Innsbruck, Austria – sequence: 7 givenname: Gottfried surname: Gruber fullname: Gruber, Gottfried organization: Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 8 givenname: Stefan surname: Schmid fullname: Schmid, Stefan organization: Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 9 givenname: Barbara surname: Friesenecker fullname: Friesenecker, Barbara organization: Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 10 givenname: Ingo H surname: Lorenz fullname: Lorenz, Ingo H organization: Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 11 givenname: Mathias surname: Ströhle fullname: Ströhle, Mathias organization: Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 12 givenname: Verena surname: Rastner fullname: Rastner, Verena organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 13 givenname: Susanne surname: Trübsbach fullname: Trübsbach, Susanne organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 14 givenname: Helmut surname: Raab fullname: Raab, Helmut organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 15 givenname: Benedikt surname: Treml fullname: Treml, Benedikt organization: Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 16 givenname: Dieter surname: Wally fullname: Wally, Dieter organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 17 givenname: Benjamin surname: Treichl fullname: Treichl, Benjamin organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria – sequence: 18 givenname: Agnes surname: Mayr fullname: Mayr, Agnes organization: Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 19 givenname: Christof surname: Kranewitter fullname: Kranewitter, Christof organization: Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 20 givenname: Elgar surname: Oswald fullname: Oswald, Elgar organization: Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28457980$$D View this record in MEDLINE/PubMed
BookMark	eNpNUNtKJDEUDIuyXtZPUPI4wsRNunuSbt9k8AaCoO7zcDo5GVvSSZukF_TD9vvs1VF8OZc6VUVx9siWDx4JORT8RHAhf98X5aJgJS_kTKjjknOlmPpBdr_grW_zDjlI6YlzLkolF7L5SXaKulqopua75N8d_sWYwNFgaY4w9sA6b0aNhuoA69GFAfLjCx1T59fUdjFl5jqPmyvkLnhqQecQJ8hr9JNLxkSn3UZMj1MNr-jp4CD1QGd35w_Xy-NTCvS_o0P2LsE5HSCCc-jYOoZxmNMwoGcOWnRzGsGb0HdpSpVjB-4X2bbgEh5s-j75c3H-sLxiN7eX18uzG6YrVWUmFmg1WmtK0FCX3GqtjVCmEa1QWhSt0U1bN7LlVimldWMKlLqSxrZS8qos9snsw3eI4XnElFdTCI3OgccwppWom7KRteD1RD3aUMe2R7MaYtdDfFl9_rp4AyniiTk
CitedBy_id	crossref_primary_10_1001_jamanetworkopen_2025_32717 crossref_primary_10_1111_trf_15749 crossref_primary_10_1186_s40779_020_00241_z crossref_primary_10_1017_cem_2019_409 crossref_primary_10_1002_adma_202301738 crossref_primary_10_1097_TA_0000000000004103 crossref_primary_10_1097_ALN_0000000000004268 crossref_primary_10_1186_s13741_025_00562_4 crossref_primary_10_1038_s41540_021_00202_9 crossref_primary_10_1001_jama_2023_11668 crossref_primary_10_1001_jama_2023_11665 crossref_primary_10_1097_ALN_0000000000005230 crossref_primary_10_1080_00325481_2024_2320080 crossref_primary_10_1002_jja2_12731 crossref_primary_10_1016_j_bpa_2023_11_003 crossref_primary_10_1213_ANE_0000000000006174 crossref_primary_10_1186_s13049_020_00790_1 crossref_primary_10_1001_jamanetworkopen_2025_32702 crossref_primary_10_1007_s00068_025_02919_2 crossref_primary_10_1111_1742_6723_13643 crossref_primary_10_1016_j_ajem_2020_07_041 crossref_primary_10_1097_MBC_0000000000001046 crossref_primary_10_1177_10760296241254106 crossref_primary_10_1001_jama_2023_21019 crossref_primary_10_1111_bjh_15524 crossref_primary_10_1055_s_0042_1757896 crossref_primary_10_1097_TA_0000000000002624 crossref_primary_10_3390_jcm10225369 crossref_primary_10_1186_s13054_019_2347_3 crossref_primary_10_1080_17474086_2018_1458610 crossref_primary_10_1055_a_2234_4021 crossref_primary_10_1016_j_medin_2023_03_007 crossref_primary_10_1111_trf_16376 crossref_primary_10_1136_tsaco_2021_000779 crossref_primary_10_1186_s12871_019_0767_x crossref_primary_10_1186_s13054_025_05269_y crossref_primary_10_1213_ANE_0000000000006756 crossref_primary_10_3390_jcm14155426 crossref_primary_10_1097_TA_0000000000003960 crossref_primary_10_1111_trf_15157 crossref_primary_10_1111_trf_16488 crossref_primary_10_1097_TA_0000000000003164 crossref_primary_10_3390_jcm10102068 crossref_primary_10_3390_jcm11144174 crossref_primary_10_5492_wjccm_v14_i1_101639 crossref_primary_10_1097_MOH_0000000000000386 crossref_primary_10_1007_s00068_019_01165_7 crossref_primary_10_1097_TA_0000000000002920 crossref_primary_10_1097_ACO_0000000000000842 crossref_primary_10_1016_j_jor_2020_03_032 crossref_primary_10_1097_ACO_0000000000001025 crossref_primary_10_1186_s13054_023_04637_w crossref_primary_10_1111_tme_13035 crossref_primary_10_7326_M24_0565 crossref_primary_10_3390_jcm10173930 crossref_primary_10_1097_MBC_0000000000001133 crossref_primary_10_1016_j_heliyon_2023_e18840 crossref_primary_10_1213_ANE_0000000000003660 crossref_primary_10_1055_a_2153_3810 crossref_primary_10_1111_vox_13542 crossref_primary_10_1097_ACO_0000000000001028 crossref_primary_10_1097_ACO_0000000000001027 crossref_primary_10_1097_SHK_0000000000001286 crossref_primary_10_1007_s12028_022_01626_9 crossref_primary_10_3390_diagnostics11091548 crossref_primary_10_3390_jcm10020320 crossref_primary_10_1016_j_injury_2019_09_032 crossref_primary_10_51893_2021_1_OA3 crossref_primary_10_1111_bjh_15737 crossref_primary_10_3390_jcm9082420 crossref_primary_10_3389_fimmu_2023_1310271 crossref_primary_10_1002_rth2_12724 crossref_primary_10_36290_vnl_2019_038 crossref_primary_10_1007_s00068_020_01563_2 crossref_primary_10_1097_TA_0000000000002262 crossref_primary_10_1007_s12185_025_03918_0 crossref_primary_10_1186_s13063_020_4141_6 crossref_primary_10_1056_NEJMc1811315 crossref_primary_10_1111_tme_12524 crossref_primary_10_1097_TA_0000000000003923 crossref_primary_10_3390_jcm9123805 crossref_primary_10_1111_trf_15917 crossref_primary_10_1016_j_redare_2023_08_001 crossref_primary_10_1213_ANE_0000000000006273 crossref_primary_10_1016_j_jclinane_2022_110874 crossref_primary_10_1002_jha2_358 crossref_primary_10_1007_s00101_018_0411_z crossref_primary_10_1016_j_medine_2023_03_019 crossref_primary_10_1097_HPC_0000000000000181 crossref_primary_10_1007_s10049_017_0361_z crossref_primary_10_1016_j_accpm_2025_101543 crossref_primary_10_1007_s10049_020_00763_y crossref_primary_10_1186_s13054_022_04178_8 crossref_primary_10_1136_tsaco_2024_001415 crossref_primary_10_1093_jbcr_iraf021 crossref_primary_10_1080_17474086_2021_1858788 crossref_primary_10_1007_s00101_023_01368_z crossref_primary_10_1016_j_transci_2023_103657 crossref_primary_10_1186_s13054_023_04537_z crossref_primary_10_36290_aim_2023_050 crossref_primary_10_1016_j_wneu_2019_09_024 crossref_primary_10_1097_TA_0000000000002200 crossref_primary_10_3390_jcm11010001 crossref_primary_10_1097_MCC_0000000000000466 crossref_primary_10_1097_SHK_0000000000001378 crossref_primary_10_1007_s00101_018_0509_3 crossref_primary_10_1097_ACO_0000000000001464 crossref_primary_10_1097_CCM_0000000000005596 crossref_primary_10_1186_s44158_025_00248_9 crossref_primary_10_1111_voxs_12376 crossref_primary_10_1111_jth_13893 crossref_primary_10_1007_s00134_021_06531_x crossref_primary_10_1177_0300060518794092 crossref_primary_10_1093_milmed_usx057 crossref_primary_10_1007_s10049_021_00912_x crossref_primary_10_1097_01_aoa_0000891584_33208_c3 crossref_primary_10_1097_ACO_0000000000001467 crossref_primary_10_1007_s40140_021_00502_0 crossref_primary_10_1097_EJA_0000000000001366 crossref_primary_10_1111_tme_12932 crossref_primary_10_3390_jcm10235484 crossref_primary_10_1186_s13017_023_00497_5 crossref_primary_10_1159_000519696 crossref_primary_10_1001_jama_2023_4080 crossref_primary_10_1097_ACO_0000000000001353 crossref_primary_10_1097_EJA_0000000000001803 crossref_primary_10_3390_jcm11133630 crossref_primary_10_1016_j_jcrc_2019_11_013 crossref_primary_10_1111_jth_14991 crossref_primary_10_3389_fped_2020_600501 crossref_primary_10_1016_j_tmrv_2021_06_007 crossref_primary_10_1016_j_accpm_2019_02_005 crossref_primary_10_1016_j_bja_2019_02_017 crossref_primary_10_1016_j_bja_2018_10_055 crossref_primary_10_1093_ajcp_aqae073 crossref_primary_10_1097_ACO_0000000000001478 crossref_primary_10_3390_ijms26031336 crossref_primary_10_1097_ALN_0000000000004520 crossref_primary_10_1097_ACO_0000000000001481 crossref_primary_10_1136_bmjopen_2021_051003 crossref_primary_10_1080_10903127_2024_2425819 crossref_primary_10_1371_journal_pone_0258192 crossref_primary_10_1136_tsaco_2023_001271 crossref_primary_10_1097_ACO_0000000000000836 crossref_primary_10_1097_TA_0000000000001942 crossref_primary_10_1007_s00134_023_07170_0 crossref_primary_10_1111_trf_14227 crossref_primary_10_1007_s40140_020_00397_3 crossref_primary_10_1159_000511271 crossref_primary_10_1186_s13054_019_2524_4 crossref_primary_10_1016_S2352_3026_17_30126_6 crossref_primary_10_1016_j_redare_2019_03_004 crossref_primary_10_3390_jcm10112268 crossref_primary_10_1213_ANE_0000000000005709 crossref_primary_10_1097_TA_0000000000002764 crossref_primary_10_1186_s13054_023_04327_7 crossref_primary_10_1016_S2352_3026_17_30125_4 crossref_primary_10_1016_S2352_3026_17_30065_0 crossref_primary_10_1007_s00068_025_02852_4 crossref_primary_10_1182_blood_2022016558 crossref_primary_10_1186_s13063_021_05524_x crossref_primary_10_1016_j_jtha_2023_07_002 crossref_primary_10_1111_1742_6723_13734 crossref_primary_10_1016_j_anclin_2021_03_010 crossref_primary_10_1097_SHK_0000000000002534 crossref_primary_10_1097_TA_0000000000003624 crossref_primary_10_1097_SHK_0000000000001207 crossref_primary_10_1002_rnc_5963 crossref_primary_10_3390_jcm12041707 crossref_primary_10_1111_trf_16502 crossref_primary_10_1097_ACO_0000000000000696 crossref_primary_10_1097_ACO_0000000000000697 crossref_primary_10_1055_a_2535_8910 crossref_primary_10_1111_trf_17835 crossref_primary_10_1097_EJA_0000000000001202 crossref_primary_10_1007_s00134_017_4895_9 crossref_primary_10_1016_j_injury_2018_11_026 crossref_primary_10_1016_j_accpm_2018_04_002 crossref_primary_10_1080_17512433_2020_1776608 crossref_primary_10_1007_s00113_023_01300_5 crossref_primary_10_1186_s13017_020_0291_9 crossref_primary_10_1007_s11239_019_01879_w crossref_primary_10_1080_17474086_2020_1758929 crossref_primary_10_1111_bjh_18275 crossref_primary_10_1016_j_accpm_2022_101180 crossref_primary_10_1007_s00068_023_02221_z crossref_primary_10_1016_j_bja_2018_05_063 crossref_primary_10_1136_emermed_2024_213925 crossref_primary_10_1136_tsaco_2022_000937 crossref_primary_10_1186_s13049_017_0443_4 crossref_primary_10_3390_jcm10204793 crossref_primary_10_1055_a_1232_7721 crossref_primary_10_3390_jcm12134289 crossref_primary_10_1136_bcr_2020_236608 crossref_primary_10_1097_MD_0000000000025099 crossref_primary_10_1007_s00101_025_01524_7 crossref_primary_10_1111_jvim_15365 crossref_primary_10_1055_a_2445_7163 crossref_primary_10_1097_MCC_0000000000001107 crossref_primary_10_1016_j_redar_2023_05_001 crossref_primary_10_1186_s13054_022_03940_2 crossref_primary_10_1055_s_0042_1756302 crossref_primary_10_1097_ALN_0000000000004711 crossref_primary_10_1007_s10049_018_0552_2 crossref_primary_10_1186_s13054_018_2086_x
ContentType	Journal Article
Copyright	Copyright © 2017 Elsevier Ltd. All rights reserved.
Copyright_xml	– notice: Copyright © 2017 Elsevier Ltd. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/S2352-3026(17)30077-7
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	2352-3026
ExternalDocumentID	28457980
Genre	Randomized Controlled Trial Journal Article
GrantInformation	None.
GroupedDBID	-RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAQQT AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ CGR CUY CVF EBS ECM EIF EJD FDB HZ~ M41 NPM O9- OC~ OO- Z5R 7X8 APXCP EFKBS
ID	FETCH-LOGICAL-c474t-15efceffd3aca830fcccd17d91b17c12bdc9b896b0f777cc9d2e6c46dfb660432
IEDL.DBID	7X8
ISICitedReferencesCount	238
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000405452100011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2352-3026
IngestDate	Sun Sep 28 11:17:44 EDT 2025 Thu Apr 03 07:08:53 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
License	Copyright © 2017 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c474t-15efceffd3aca830fcccd17d91b17c12bdc9b896b0f777cc9d2e6c46dfb660432
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
PMID	28457980
PQID	1893968108
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1893968108 pubmed_primary_28457980
PublicationCentury	2000
PublicationDate	2017-06-01
PublicationDateYYYYMMDD	2017-06-01
PublicationDate_xml	– month: 06 year: 2017 text: 2017-06-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	The Lancet. Haematology
PublicationTitleAlternate	Lancet Haematol
PublicationYear	2017
References	28583287 - Lancet Haematol. 2017 Jun;4(6):e257 28583282 - Lancet Haematol. 2017 Jun;4(6):e245 28754193 - Lancet Haematol. 2017 Aug;4(8):e348
References_xml	– reference: 28583287 - Lancet Haematol. 2017 Jun;4(6):e257 – reference: 28583282 - Lancet Haematol. 2017 Jun;4(6):e245 – reference: 28754193 - Lancet Haematol. 2017 Aug;4(8):e348
SSID	ssj0001376569
Score	2.50954
Snippet	Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	e258
SubjectTerms	Adolescent Adult Aged Aged, 80 and over Blood Coagulation Factors - therapeutic use Female Hemorrhage - drug therapy Hemorrhage - etiology Humans Male Middle Aged Plasma Treatment Outcome Wounds and Injuries - complications Young Adult
Title	Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial
URI	https://www.ncbi.nlm.nih.gov/pubmed/28457980 https://www.proquest.com/docview/1893968108
Volume	4
WOSCitedRecordID	wos000405452100011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fSxwxEA62ltKXWm1trW2J4IPCBTe7m2TjixRRWqiHWFvu7civscK6e_XuCvqH9e_rJLv2ngTBl8AmmyUws5lvJpP5CNlWEjyY0jMhXM5KgxjOcFMwA9YoFTKRJRaFn9_UcFiNRvq0D7hN-7TKuz0xbdS-dTFGvsfRsOpYPKs6mPxmkTUqnq72FBpPyHKBUCZqtRpVixgL_j0isdrliDNYgf7G4hLP3vf_nTtc7RaxsA1T9wPNZHCOVx671FfkZQ816edON1bJUmjWyPOT_jD9Nfl7FmJOBr7SAp1dm_mVYeiho6w9da25mNdt5Cu-oTE3_oLCJQJFFlFpP5pkSjvCHuxqujxPhK4UnwHd-F_YtrehoROE6FeG7pwdnX893N2nhsYv1oGlKWFAYwHyug41S5dMBjRyejHUz1APKBpT36I24qoSxcgb8uP46PzwC-tpHJgrVTljXARwAcAXxpmqyMA557nymluuHM-td9pWWtoMlFLOaZ8H6UrpwUoZKwauk6dN24R3hAoLpUSPV-ToNgoRjLQ5aOBSQxG49Rtk604iY1xYPPswTWjn0_FCJhvkbSfW8aSr5zFGCy2UrrL3D5i9SV7k0bCnOMwHsgy4SYSP5Jn7M7ucXn9K-oft8PTkH9pf6KA
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reversal+of+trauma-induced+coagulopathy+using+first-line+coagulation+factor+concentrates+or+fresh+frozen+plasma+%28RETIC%29%3A+a+single-centre%2C+parallel-group%2C+open-label%2C+randomised+trial&rft.jtitle=The+Lancet.+Haematology&rft.au=Innerhofer%2C+Petra&rft.au=Fries%2C+Dietmar&rft.au=Mittermayr%2C+Markus&rft.au=Innerhofer%2C+Nicole&rft.date=2017-06-01&rft.issn=2352-3026&rft.eissn=2352-3026&rft.volume=4&rft.issue=6&rft.spage=e258&rft_id=info:doi/10.1016%2FS2352-3026%2817%2930077-7&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3026&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3026&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3026&client=summon